Vicore Pharma Holding AB VICO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vicore Publishes Prospectus Relating to the Rights Issue
-
Vicore Announces Additional Subscription Undertaking from HealthCap
-
Vicore Initiates the Global, Randomized Phase 2b ASPIRE Trial Evaluating the Disease-Modifying Potential of Buloxibutid in Idiopathic Pulmonary Fibrosis
-
Vicore Announces Presentations at the European Respiratory Society Congress 2024
-
Interim Report April-June 2024
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 28
- Website
- https://www.vicorepharma.com
Comparables
Valuation
|
Metric
|
VICO
|
CALTX
|
EGTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.85 | 104.39 | 3.20 |
Price/Sales | 7.67 | 6.92 | 17.68 |
Price/Cash Flow | — | — | — |
Price/Earnings
VICO
CALTX
EGTX
Financial Strength
|
Metric
|
VICO
|
CALTX
|
EGTX
|
|---|---|---|---|
Quick Ratio | 11.98 | 2.59 | 1.55 |
Current Ratio | 11.98 | 2.69 | 1.56 |
Interest Coverage | — | −5.22 | −22.42 |
Quick Ratio
VICO
CALTX
EGTX
Profitability
|
Metric
|
VICO
|
CALTX
|
EGTX
|
|---|---|---|---|
Return on Assets (Normalized) | −40.50% | −28.79% | −49.14% |
Return on Equity (Normalized) | −44.50% | −174.85% | −65.52% |
Return on Invested Capital (Normalized) | −50.16% | −36.60% | −56.41% |
Return on Assets
VICO
CALTX
EGTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Sphpwzlhk | Slxr | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tkgzjpmv | Xgdvhl | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tlxyxgh | Zjywpz | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tstxtcdp | Fvqnv | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Nlntyszh | Pmgy | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Sztvsfjw | Mgtt | $28.0 Bil | |||
| Moderna Inc
MRNA
| Ycfjmgh | Hmly | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Vvxscmrc | Ssmp | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rklshjyb | Chnjnk | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Rljcykdsdt | Mpctw | $12.6 Bil |
United States